Myelofibrosis Clinical Trial Update: The Science Behind JAK Inhibitors

Description: With the knowledge clinicians are gaining about the driver mutations of myeloproliferative neoplasms (MPNs), JAK inhibitors have become more recognized as a personalized, targeted therapy. But how do JAK inhibitors actually work? Dr. David Snyder from City of Hope explains what these medicines actual inhibit and goes on to discuss different variations of JAK inhibitors. Dr. Snyder shares information about approved JAK inhibitors and others in clinical trials, such as the PAC203 trial for pacritinib.

Get email alerts | http://www.patientpower.inf...

Subscribe on YouTube |
Like on Facebook |
Follow on Twitter |
Follow on Google+ |
Shared By : P2Professional
Posted on : 10/25/17
Added : 2 years ago